Reinhold Munker
Hematology · Lexington, KYNPI 1578560322
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,818 of the $7,558 with a category attached, or 77.0%. Novartis accounts for 60.1% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $2,418, 4.8 times the $500 reported in 2019.
Across 20 payments — averaging $377.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Gilead$2K
- AstraZeneca$422
- Johnson & Johnson$266
- Jazz Pharmaceuticals Inc.$224
- Sirtex Medical Inc$154
- plus $247 from 4 others
Across 43 payments — averaging $101,288 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4M
- Eli Lilly$260K
- Incyte Corporation$39K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- AbbVie$3K
What the payments were for
- Consulting fees$5,81877%
- Speaking & faculty fees$1502%
- Travel & lodging$401%
- Food & beverage$1,52220%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $4,546 |
| Gilead | 1 | $1,700 |
| AstraZeneca | 3 | $422 |
| Johnson & Johnson | 2 | $266 |
| Jazz Pharmaceuticals Inc. | 2 | $224 |
| Sirtex Medical Inc | 1 | $154 |
| Beigene USA, Inc. | 2 | $131 |
| AbbVie | 1 | $73 |
| Merck | 2 | $28 |
| Morphosys, US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 96 | $1,476,221 |
| JakafiRuxolitinib Phosphate | 35 | $538,504 |
| ScemblixAsciminib Hydrochloride | 22 | $459,877 |
| SprycelDasatinib | 34 | $415,590 |
| BosulifBosutinib | 23 | $299,060 |
| CalquenceAcalabrutinib Maleate | 22 | $226,813 |
| Lenalidomide | 16 | $225,825 |
| TasignaNilotinib Hcl | 17 | $201,694 |
| VenclextaVenetoclax | 14 | $88,337 |
| Imatinib Mesylate | 31 | $8,437 |
| Fluconazole | 31 | $3,155 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $2,328 |
| Acyclovir | 80 | $1,296 |
| Dapsone | 22 | $933 |
| Oxycodone Hcl | 21 | $787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix, Tasigna | $4,546 | $661,57139 claims |
| AstraZenecaCalquence | $422 | $226,81322 claims |
| AbbVieVenclexta | $73 | $88,33714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other hematology in Lexington
- Shams ShakilLexington$1K
- Rachel HarperLexington$473
- Fevzi YalnizLexington$405
- Gregory MonohanLexington$133
- Judith LinLexington$61
- Roger HerzigLexington$53
- Rupinder BrarLexington$51
- Zena ChahineLexington$13
- Robert EmmonsLouisville$8K
- Hassaan YasinLouisville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.